Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

Breast Cancer Research and Treatment

Volumn 48, Issue 1, 1998, Pages 11-20

  Makris, A ^a,e   Powles, T J ^a   Allred, D C ^b   Ashley, S ^a   Ormerod, M G ^d   Titley, J C ^d   Dowsett, M ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Estrogen receptor; Ki67; Progesterone receptor; S phase fraction; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; MARKER; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; PLOIDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; RECEPTORS, CELL SURFACE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0031881602     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005973529921     Document Type: Article

References (35)

1. Mouridsen H, Palshof T, Patterson L, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131-141, 1978
2. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: Estrogen receptor status: an important variable in predicting response to endocrine therapy in advanced breast cancer. Eur J Cancer 16: 323-331, 1980
3. Saez RA, Osborne CK: Hormonal treatment of advanced breast cancer. In: Kennedy BJ (ed) Current Clinical Oncology. Alan R Liss Inc, New York, 1989, pp 163-172
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992
5. Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as single adjuvant agent in the management of early breast cancer: analysis of six years. Lancet 1: 836-840, 1985
6. Fisher B, Constantino J, Redmond C et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479-484, 1989
7. Preece PE, Wood RAB, Mackie CR, Cushieri A: Tamoxifen as initial sole treatment in localized breast cancer in elderly women: A pilot study. Br Med J 284: 869-870, 1982
8. Bradheer JW, Kingdon J: Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 9: 31-34, 1983
9. Bates T, Riley D, Houghton J, Fallowfield L, Baum M: Tamoxifen alone is not adequate treatment for most elderly patients with operable breast cancer. Breast 1: 117-118, 1992
10. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433-1439, 1984
11. Ravdin PM, Green S, Melink Dorr T et al.: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291, 1992
12. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA: Adjuvant chemotherapy with or without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459-471, 1986
13. Mouridsen HT, Andersen AP, Brincker H et al.: Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group Trials. NCI Monographs 1: 115-118, 1986
14. Pritchard KI, Meakin JW, Boyd NF et al.: Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: an update. Adjuvant Ther Cancer 5: 391-400, 1987
15. Silvestrini R, Daidone MG, Bertuzzi A et al.: Relationshhip between estrogen receptors and cellular proliferation. Recent Results Cancer Res 91: 163-168, 1984
16. Howell A, Harland RNL, Barnes DM et al.: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300-304, 1987
17. Namer M, Lalanne C, Baulieu E: Increase in progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40: 1750-1752, 1980
18. Brifford M, Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Gilles F, Rouesse J: Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry 13: 250-258, 1992
19. Sarkaria JN, Gibson DFC, Jordan VC et al.: Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Research 53: 4413-4417, 1993
20. Schwartz M: Estimates of lead time and length bias in a breast cancer screening program. Cancer 46: 844-851, 1980
21. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993
22. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of Bcl-2 and Ki67 expression in oestrogen-receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A: 1663-1669, 1995
23. Paradiso A, Tommasi S, Mangia A, Lorusso V, Simone G, De Lena M: Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Research 50: 2958-2962, 1990
24. Makris A, Powles TJ, Dowsett M, Trott PA, Osborne CK, Fernando IN, Ashley SE, Ormerod MG, Titley J, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research, in press
25. Walker KJ, Bouzubar N, Robertson J, Ellis IO, Elston CW, Blamey RW, Wilson DW, Griffiths K, Nicholson RI: Immunocytochemical localization of estrogen receptor in human breast tussue. Cancer Res 48: 6517-6522, 1988
26. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 125: 107-113, 1990
27. Ormerod MG: Flow cytometry, A practical approach. Oxford University Press, Oxford, 1994
28. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977
29. Makris A, Powles TJ, Ashley SE, Dowsett M, Allred DC, Trott PA, Osborne CK, Chang J, Gregory K, Nash AG, Querci della Rovere U: A randomized trial of neoadjuvant chemoendocrine therapy in operable breast cancer. Proc Annu Meet Am Soc Clin Oncol 15: 96, 1996
30. Gorczyca W, Tuziak T, Kram A et al.: Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 15: 169-175, 1994
31. Dowsett M, Ellis PA, Saccani-Jotti G, Johnston SRD, Salter J, Anderson E, Nicholson R, Howell A: Tamoxifen and the pure antioestrogen ICI 182780 induce apoptosis in oestrogen receptor positive primary breast cancer in vivo. Proceedings of the American Association for Cancer Research 37: 185-186, 1996
32. Gerdes J, Lempke H, Baisch H et al.: Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983
33. Mauri FA, Girlando S, Palma PD, Buffa G, Perrone G, Doglioni C, Kreipe H, Barbareschi M: Ki67 antibodies (KiS5, MIB-1 and Ki67) in breast carcinomas: a brief quantitative comparison. Appl Immunohistochem 2: 171-176, 1994
34. Greenbaum E, Koss LG, Sherman AB et al.: Comparison of needle aspiration and solid biopsy technique in the flow cytometric study of DNA distributions of surgically resected tumours. Am J Clin Pathol 32: 559-564, 1984
35. Murray PA, Gomm J, Ricketts D, Powles TJ, Coombes RC: The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer 30A: 1218-1222, 1994